Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8781425 | Journal of Minimally Invasive Gynecology | 2018 | 20 Pages |
Abstract
Since publication of the Suppression of Ovarian Function Trial data, bilateral oophorectomy has been recommended for some women with premenopausal breast cancer to facilitate breast cancer treatment with aromatase inhibitors. These women may be at elevated risk for occult abdominal pathology compared with the general population. Gynecologic surgeons often perform castration oophorectomy in patients with breast cancer as an increasing number of oncologists are using aromatase inhibitors to treat premenopausal breast cancer. Our data suggest that other abdominal/pelvic cancers, precancerous conditions, and previously unrecognized metastatic disease are not uncommon findings in this patient population. Gynecologists serving this patient population may consider a careful abdominal survey, pelvic washings, endometrial sampling, and serial sectioning of fallopian tube specimens for a thorough evaluation.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Lara F.B. MD, MPH, Vandana G. MD, Jimena MD, Christopher MD, MPH, Hye-Chun MD, Katherine MD, Patricia MD, Beau MD, Carolyn MD, Farinaz MD, Mallory MD, Amanda DO, MSCR,